Hepatic Ketone Production as the Governing Factor in Determining Fatty Liver and Type 2 Diabetes

Chair(s)

• 

  Barbara Gower, PhD (she/her/hers)

  Department Chair and Professor, Department of Nutrition Sciences
  Nutrition Sciences
  The University of Alabama at Birmingham
  irondale, Alabama, United States

  Disclosure(s): Cook Keto: Advisory Committee/Board Member (Ongoing)
  NIDDK: Grant/Research Support (Ongoing)
• EP

  Eric Plaisance, PhD

  Associate Professor and Vice Chair
  The University of Alabama at Birmingham
  Vincent, Alabama, United States

  Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

Speaker(s)

• JB

  Jeffrey Browning, MD

  Professor and Chair, Clinical Nutrition
  UT Southwestern Medical Center
  Dallas, Texas, United States

  Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.
• 

  Peter Crawford, MD, PhD (he/him/his)

  Professor of Medicine and Vice Dean for Research, Medical School
  Department of Medicine
  University of Minnesota
  Minneapolis, Minnesota, United States

  Disclosure(s): Selah Therapeutics: Consultant (Ongoing)
• 

  Gerald Shulman, MD, PhD, MACP, MACE, FRCP

  George R. Cowgill Professor of Medicine and Cellular and Molecular Physiology
  Yale School of Medicine
  New Haven, Connecticut, United States

  Disclosure(s): Aro Biotherapeutics: Consultant (Ongoing)
  Arrowhead Pharmaceuticals: Speaker/Speaker's Bureau (Terminated, December 18, 2023)
  AstraZeneca: Consultant (Terminated); Grant/Research Support (Terminated)
  Bayer AG: Consultant (Ongoing)
  Betagenon AB: Consultant (Ongoing)
  DiCerna Pharmaceuticals, Inc.: Consultant (Ongoing)
  Equator Therapeutics: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Esperion Therapeutics: Consultant (Ongoing)
  Eternygen GmbH: Consultant (Terminated, January 1, 2024)
  Fortress Biotech: Consultant (Ongoing)
  Generian Pharmaceuticals: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  iMetabolic Biopharma Corporation: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Janssen: Consultant (Terminated, January 1, 2024); Speaker/Speaker's Bureau (Terminated, January 1, 2024)
  Kriya Therapeutics,: Consultant (Ongoing)
  Levels Health: Stock Shareholder (excluding mutual funds) (Ongoing)
  Mammoth BioSciences, Inc: Consultant (Ongoing)
  Maze Therapeutics, Inc.: Consultant (Terminated, January 1, 2023); Grant/Research Support (Terminated, January 1, 2023)
  Merck Pharmaceuticals: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Novo Nordisk: Consultant (Ongoing)
  OrsoBio: Stock Shareholder (excluding mutual funds) (Ongoing)

Presentations:

• 10:00 AM – 10:05 AM CT

  Welcome and Introductions - Hepatic Ketone Production as the Governing Factor in Determining Fatty Liver and Type 2 Diabetes
  

  Speaker: Barbara Gower, PhD (she/her/hers) – The University of Alabama at Birmingham
• 10:00 AM – 10:25 AM CT

  MRS and Mass Spectrometry: Windows into the Inner Workings of Metabolic Disease
  

  Speaker: Gerald I. Shulman, MD, PhD, MACP, MACE, FRCP – Yale School of Medicine
• 10:25 AM – 11:15 AM CT

  Tracing Hepatic Metabolism in Health and Disease
  

  Speaker: Jeffrey D. Browning, MD – UT Southwestern Medical Center
• 10:50 AM – 11:15 AM CT

  Multi-Dimensional Roles of Ketones in Fuel Metabolism and Therapeutics
  

  Speaker: Peter Crawford, MD, PhD (he/him/his) – University of Minnesota
• 11:15 AM – 11:30 AM CT

  Panel Discussion - Hepatic Ketone Production as the Governing Factor in Determining Fatty Liver and Type 2 Diabetes
  

  Chair: Barbara Gower, PhD (she/her/hers) – The University of Alabama at Birmingham

  Chair: Eric P. Plaisance, PhD – The University of Alabama at Birmingham

  Speaker: Jeffrey D. Browning, MD – UT Southwestern Medical Center

  Speaker: Peter Crawford, MD, PhD (he/him/his) – University of Minnesota

  Speaker: Gerald I. Shulman, MD, PhD, MACP, MACE, FRCP – Yale School of Medicine